# BLOOD CELL TECHNOLOGIES, LLC: Development of Second Generation BLVRB Inhibitors for Treating Chemotherapy Induced Thrombocytopenia

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | BLOOD CELL TECHNOLOGIES, LLC |
| Location | Stony Brook, NY |
| Project | Development of Second Generation BLVRB Inhibitors for Treating Chemotherapy Induced Thrombocytopenia |
| Project number | 4R44CA302180-02 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $875,125 |
| Awarded | 2026-09-17 |
| Project period | 2025-09-01 to 2028-08-31 |
| UEI | HH9LT9M9B3N4 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11457446). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.